How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of maximal effort cytoreductive surgery for advanced ovarian cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    Additional information considered by IPAC

    Professional experts' opinions

    Expert advice was sought from consultants who have been nominated or ratified by their professional Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by professional experts, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, when comments are considered voluminous, or publication would be unlawful or inappropriate.

    10 professional expert questionnaires were submitted and can be found on the NICE website.

    Patient organisation opinions

    Patient organisation submissions were received and can be found on the NICE website.

    Patient commentators' opinions

    NICE received 14 questionnaires from patients who had the procedure (or their carers).

    Patients' views on the procedure were consistent with the published evidence and the opinions of the professional experts. See the patient commentary summary for more information.

    Company engagement

    A structured information request was sent to 1 company who manufactures a potentially relevant device for use in this procedure. NICE received 1 completed submission. This was considered by the IP team and any relevant points have been taken into consideration when preparing this overview.

    Issues for consideration by IPAC

    Evidence on recurrent ovarian cancer has not been included.

    Ongoing trials:

    • Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (NCT02828618); Randomised controlled trial; US, Austria, Denmark, France, Germany, Italy, Sweden, UK; n=797; estimated completion date April 2023.

    • Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE); randomised controlled trial; US; n=580; estimated completion date May 2023.